[go: up one dir, main page]

MXPA01004310A - Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl). - Google Patents

Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).

Info

Publication number
MXPA01004310A
MXPA01004310A MXPA01004310A MXPA01004310A MXPA01004310A MX PA01004310 A MXPA01004310 A MX PA01004310A MX PA01004310 A MXPA01004310 A MX PA01004310A MX PA01004310 A MXPA01004310 A MX PA01004310A MX PA01004310 A MXPA01004310 A MX PA01004310A
Authority
MX
Mexico
Prior art keywords
differentiation
psgl
cytotoxic
antagonists
inhibition
Prior art date
Application number
MXPA01004310A
Other languages
English (en)
Inventor
Narasimhaswamy Manjunath
Original Assignee
Cbr Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbr Lab Inc filed Critical Cbr Lab Inc
Publication of MXPA01004310A publication Critical patent/MXPA01004310A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen metodos para inhibir la diferenciacion de una celula T activada hacia un linfocito citotoxico en un sujeto mamifero, que comprende administrar a un sujeto una cantidad terapeuticamente efectiva de un antagonista PSGL.
MXPA01004310A 1998-10-30 1999-10-29 Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl). MXPA01004310A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10631598P 1998-10-30 1998-10-30
PCT/US1999/025501 WO2000025808A1 (en) 1998-10-30 1999-10-29 Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists

Publications (1)

Publication Number Publication Date
MXPA01004310A true MXPA01004310A (es) 2003-06-06

Family

ID=22310736

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01004310A MXPA01004310A (es) 1998-10-30 1999-10-29 Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).

Country Status (11)

Country Link
US (1) US20020058034A1 (es)
EP (1) EP1131084A4 (es)
JP (1) JP2002528513A (es)
CN (1) CN1342085A (es)
AU (2) AU774419C (es)
BR (1) BR9914957A (es)
CA (1) CA2347119A1 (es)
IL (1) IL142717A0 (es)
MX (1) MXPA01004310A (es)
NZ (1) NZ528610A (es)
WO (1) WO2000025808A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7223848B2 (en) * 2001-06-05 2007-05-29 Genetics Institute, Llc Methods for purifying Fc-containing proteins
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
WO2003089450A2 (en) * 2002-04-22 2003-10-30 Recopharma Ab Fusion polypeptides and methods for inhibiting microbial adhesion
US20040208877A1 (en) * 2002-07-01 2004-10-21 Avigdor Levanon Antibodies and uses thereof
CN1678348A (zh) * 2002-07-01 2005-10-05 萨文特医药公司 用于治疗性治疗的组合物和方法
US20040202665A1 (en) * 2002-07-01 2004-10-14 Janette Lazarovits Compositions and methods for therapeutic treatment
JP2005536199A (ja) * 2002-07-01 2005-12-02 サビエント ファーマシューティカルズ，インコーポレイティド 抗体及びそれらの使用
US20050152906A1 (en) * 2003-06-30 2005-07-14 Avigdor Levanon Specific human antibodies
US20050266009A1 (en) * 2003-06-30 2005-12-01 Savient Pharmaceuticals, Inc. Antibodies and uses thereof
US20050069955A1 (en) * 2003-06-30 2005-03-31 Daniel Plaksin Antibodies and uses thereof
EP1689776A2 (en) * 2003-11-12 2006-08-16 Wisconsin Alumni Research Foundation Equine p-selectin glycoprotein ligand-1 and uses thereof
UY28886A1 (es) * 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
BRPI0510561A (pt) 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
WO2006130620A2 (en) * 2005-05-31 2006-12-07 President And Fellows Of Harvard College Modulation of t cell recruitment
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
PL3494986T3 (pl) 2008-08-14 2020-11-16 Acceleron Pharma Inc. Pułapki GDF
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
EP4079324A1 (en) 2014-07-08 2022-10-26 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH30906A (en) * 1991-07-25 1997-12-23 Idec Pharma Corp Induction of cytotoxic t-lymphocyte responses.
US5747036A (en) * 1991-08-28 1998-05-05 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
EP1396542B1 (en) * 1992-10-23 2011-03-09 Genetics Institute, LLC P-Selectin Ligand Protein
AU681369B2 (en) * 1992-11-16 1997-08-28 Board Of Regents Of The University Of Oklahoma, The Glycoprotein ligand for P-selectin and methods of use thereof
US5614615A (en) * 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5659018A (en) * 1995-08-01 1997-08-19 Genetics Institute, Inc. Mocarhagin, a cobra venom protease, and therapeutic uses thereof
ES2208759T3 (es) * 1995-08-03 2004-06-16 Board Of Regents Of The University Of Oklahoma O-glicanos inhibidores de la inflamacion mediada por selectina.
US5962318A (en) * 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy

Also Published As

Publication number Publication date
WO2000025808A9 (en) 2001-07-19
IL142717A0 (en) 2002-03-10
NZ528610A (en) 2005-03-24
CA2347119A1 (en) 2000-05-11
AU3097100A (en) 2000-05-22
EP1131084A4 (en) 2001-12-19
AU774419C (en) 2005-03-03
EP1131084A1 (en) 2001-09-12
JP2002528513A (ja) 2002-09-03
WO2000025808A1 (en) 2000-05-11
WO2000025808A8 (en) 2000-10-26
AU2004214516A1 (en) 2004-10-14
US20020058034A1 (en) 2002-05-16
AU774419B2 (en) 2004-06-24
CN1342085A (zh) 2002-03-27
BR9914957A (pt) 2001-07-24

Similar Documents

Publication Publication Date Title
MXPA01004310A (es) Inhibicion de diferenciacion de celulas t citotoxicas mediante antagonistas de ligando de p-selectina (psgl).
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
GB2340121B (en) Delivery system
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
AU2272097A (en) Drug delivery compositions suitable for intravenous injection
GEP20074144B (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CA2384111A1 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
EP0833619A4 (en) SUBLINGUAL OR BUKAL ADMINISTRATED SUBSTANCES
AR022254A1 (es) Composicion de administracion oral.
MX9800125A (es) Nuevas composiciones medicinales estables para generar aerosoles libres de gas propulsor.
AU2344295A (en) Inherently light- and heat-stabilized polyamides
NZ306653A (en) Isolated dna il-17 receptors
DK1255738T3 (da) Gonadotropin-frigivende hormonreceptor-antagonister og fremgangsmåder relateret dertil
IL137266A0 (en) Heterocyclic chemokine receptor antagonists and pharmaceutical compositions containing the same
NZ509809A (en) Thienol[2,3-d]pyrimidinediones which exhibit immunosuppressive activity
SI1588706T1 (sl) Tableta valsartana
AU8912898A (en) Methods for inhibiting detrimental side-effects due to gnrh or gnrh agonist administration
MX9801890A (es) Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen.
ATE194753T1 (de) Hyperkinetische bewegungsstörung modulierender opiatrezeptor-antagonist
ES2135342A1 (es) Procedimiento para prevenir el cancer de mama.
NZ292429A (en) Combination of non-narcotic analgesic and nmda receptor antagonist for alleviating pain
IL129359A0 (en) Bi-aromatic compounds bound by a heteroethynylene radical and pharmaceutical and cosmetic compositions containing same
WO2001009119A3 (en) Chemokine receptor antagonists
PT822827E (pt) Antagonistas de lhrh
AU9392198A (en) Methods for increasing cd4+ t-lymphocyte counts in hiv-infected patients by the administration of gm-csf